Back to top
more

Bayer (BAYRY)

(Delayed Data from OTC)

$7.26 USD

7.26
620,543

-0.11 (-1.49%)

Updated Apr 24, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 11% (224 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales

by Zacks Equity Research

Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.

Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea

by Zacks Equity Research

The U.S. Department of Justice files a complaint against Regeneron (REGN), alleging fraudulent drug pricing practices related to its lead drug, Eylea.

Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks

by Zacks Equity Research

Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.

Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges

by Zacks Equity Research

Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.

Thermo Fisher (TMO) Inks Deal to Develop Companion Diagnostics

by Zacks Equity Research

Thermo Fisher's (TMO) new partnership with Bayer AG is likely to help increase the latter's precision cancer therapies.

Bayer's (BAYRY) Elinzanetant Meets Goals in Third Phase III Study

by Zacks Equity Research

Bayer's (BAYRY) pipeline candidate, elinzanetant, achieves primary and secondary goals in late-stage OASIS 3 study supporting submissions for marketing authorization.

Bayer (BAYRY) Q4 Earnings Top, Crop Science Unit Drives Revenues

by Zacks Equity Research

Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2023, primarily driven by increased sales of Crop Science and Pharmaceuticals products.

Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug

by Zacks Equity Research

Bayer (BAYRY) acquires exclusive marketing rights for cardiovascular drug acoramidis in Europe from BridgeBio for an upfront payment of $310 million.

Bayer (BAYRY) Intends to Slash Dividends Amid Challenges

by Zacks Equity Research

Bayer (BAYRY) announced plans to cut dividends to pay out only the legally required minimum for three years in the wake of high debt and increasing legal costs.

Regeneron (REGN) Q4 Earnings & Sales Top, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) beats earnings and sales estimates in fourth-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, continue to fall.

Regeneron (REGN) Down as Q4 Eylea Preliminary Sales Disappoint

by Zacks Equity Research

Regeneron (REGN) shares decline after it announces preliminary Q4 sales for the ophthalmology drug Eylea.

Bayer (BAYRY) Elinzanetant Meets Goals in Late-Stage Studies

by Zacks Equity Research

Bayer's (BAYRY) experimental candidate, elinzanetant, for the non-hormonal treatment of moderate to severe vasomotor symptoms, meets primary and secondary goals in phase III studies.

Bayer (BAYRY) Loses 28% in 2023: What to Expect in 2024?

by Zacks Equity Research

Bayer (BAYRY) faced challenges in 2023 as sales declined in the Crop Science division. Pipeline setbacks also weighed on the stock.

EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data

by Zacks Equity Research

EyePoint (EYPT) announces positive top-line data from the phase II study of its investigational candidate, EYP-1901, in the treatment of wet age-related macular degeneration. The stock rallies 178%.

Bristol Myers (BMY), TSVT Cell Therapy Abecma Faces Setback

by Zacks Equity Research

Bristol Myers Squibb (BMY) and 2seventy bio, Inc.'s efforts to seek approval for the label expansion of Abecma for earlier lines of treatment face a roadblock.

Bayer (BAYRY) Stops Heart Drug Study Due to Lack of Efficacy

by Zacks Equity Research

Bayer's (BAYRY) phase III cardiovascular drug study is stopped due to low efficacy compared with Eliquis. The company suffers another setback in Roundup Litigation.

Bayer's (BAYRY) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Bayer (BAYRY) reports weaker-than-expected third-quarter 2023 results. Management maintains its 2023 outlook.

Regeneron (REGN) Q3 Earnings & Sales Top, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) beats earnings and sales estimates in third-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, fall yet again.

New Strong Sell Stocks for October 17th

by Zacks Equity Research

BAYYR, EDAP and FWRD have been added to the Zacks Rank #5 (Strong Sell) List on October 17, 2023.

Roche's (RHHBY) Vabysmo Positive in Late-Stage RVO Studies

by Zacks Equity Research

Roche (RHHBY) Vabysmo maintains vision improvements with extended treatment intervals of up to four months in phase III studies for retinal vein occlusion.

Bayer (BAYRY) Partners Twist Bioscience for Drug Discovery

by Zacks Equity Research

Bayer (BAYRY) collaborates with Twist Bioscience to advance breakthrough innovations based on new scientific approaches and platform technologies.

Hologic (HOLX) to Boost Breast Imaging Modality With New Pact

by Zacks Equity Research

Hologic's (HOLX) collaboration with Bayer will enable physicians everywhere to include CEM in their breast cancer diagnosis workflows.

Regeneron (REGN) Gains 13% in 1 Month on FDA Nod For Eylea HD

by Zacks Equity Research

Regeneron (REGN) gains 13% in a month on the FDA's approval of a higher dose of Eylea and other positive updates.

New Strong Sell Stocks for August 25th

by Zacks Equity Research

ALCO, BAYRY and CCBG have been added to the Zacks Rank #5 (Strong Sell) List on August 25, 2023.

Regeneron (REGN) Gets FDA Nod for Higher Dose of Eylea

by Zacks Equity Research

Regeneron (REGN) obtains FDA approval for a higher dose of aflibercept injection under the brand name Eylea HD for various ophthalmology indications. The regulatory body also approves Veopoz.